NASDAQ:QDEL - US2197981051 - Common Stock
The current stock price of QDEL is 27.65 USD. In the past month the price increased by 5.98%. In the past year, price decreased by -34.56%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 26.91 | 229.51B | ||
ISRG | INTUITIVE SURGICAL INC | 58.19 | 167.93B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.14 | 155.75B | ||
SYK | STRYKER CORP | 30.42 | 149.44B | ||
MDT | MEDTRONIC PLC | 16.64 | 117.93B | ||
BDX | BECTON DICKINSON AND CO | 13.64 | 55.79B | ||
IDXX | IDEXX LABORATORIES INC | 53.4 | 51.31B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.46 | 47.47B | ||
RMD | RESMED INC | 29.93 | 41.84B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 16.01 | 34.05B | ||
DXCM | DEXCOM INC | 44.68 | 29.79B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.53 | 26.58B |
QuidelOrtho Corp. operates as a vitro diagnostics company. The company is headquartered in San Diego, California and currently employs 6,600 full-time employees. The firm specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. The company provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.
QUIDELORTHO CORP
9975 Summers Ridge Road
San Diego CALIFORNIA 92121 US
CEO: Douglas C. Bryant
Employees: 6600
Phone: 18585521100
The current stock price of QDEL is 27.65 USD. The price decreased by -0.9% in the last trading session.
The exchange symbol of QUIDELORTHO CORP is QDEL and it is listed on the Nasdaq exchange.
QDEL stock is listed on the Nasdaq exchange.
15 analysts have analysed QDEL and the average price target is 44.88 USD. This implies a price increase of 62.31% is expected in the next year compared to the current price of 27.65. Check the QUIDELORTHO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
QUIDELORTHO CORP (QDEL) has a market capitalization of 1.88B USD. This makes QDEL a Small Cap stock.
QUIDELORTHO CORP (QDEL) currently has 6600 employees.
QUIDELORTHO CORP (QDEL) has a support level at 25.66 and a resistance level at 27.69. Check the full technical report for a detailed analysis of QDEL support and resistance levels.
The Revenue of QUIDELORTHO CORP (QDEL) is expected to decline by -2.3% in the next year. Check the estimates tab for more information on the QDEL EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
QDEL does not pay a dividend.
QUIDELORTHO CORP (QDEL) will report earnings on 2025-11-06, after the market close.
The PE ratio for QUIDELORTHO CORP (QDEL) is 11.82. This is based on the reported non-GAAP earnings per share of 2.34 and the current share price of 27.65 USD. Check the full fundamental report for a full analysis of the valuation metrics for QDEL.
The outstanding short interest for QUIDELORTHO CORP (QDEL) is 9.83% of its float. Check the ownership tab for more information on the QDEL short interest.
ChartMill assigns a technical rating of 1 / 10 to QDEL. When comparing the yearly performance of all stocks, QDEL is a bad performer in the overall market: 90.65% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to QDEL. While QDEL is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months QDEL reported a non-GAAP Earnings per Share(EPS) of 2.34. The EPS decreased by -4.1% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -7.31% | ||
ROE | -16.7% | ||
Debt/Equity | 0.74 |
15 analysts have analysed QDEL and the average price target is 44.88 USD. This implies a price increase of 62.31% is expected in the next year compared to the current price of 27.65.
For the next year, analysts expect an EPS growth of 31.32% and a revenue growth -2.3% for QDEL